CNTB — Connect Biopharma Holdings Income Statement
0.000.00%
Last trade - 00:00
HealthcareSpeculativeSmall Cap
- $98.81m
- $99.23m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 62.2 | 110 | 198 | 631 | 806 |
Operating Profit | -62.2 | -110 | -198 | -631 | -806 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -93.9 | -169 | -779 | -1,305 | -795 |
Provision for Income Taxes | |||||
Net Income After Taxes | -93.9 | -169 | -779 | -1,307 | -797 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -77 | -169 | -779 | -1,307 | -797 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -77 | -169 | -779 | -1,307 | -797 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.38 | -3.02 | -14 | -22.7 | -13.5 |